poisar

Stocks · News reference

Zevra Therapeutics Says Expects To Continue Engagement With The U.S. FDA In The H2 2026 To Explore Pathways To Accelerate Clinical Development

Aug 5, 2026, 11:26 PMBenzinga Newsdesk

Enrolled four patients in the event-driven Phase 3 DiSCOVER trial of celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome during Q2 2026, bringing the total number of enrolled patients to 66, with a total of

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ZVRA
Source
benzinga
Observed
Aug 5, 2026, 11:26 PM
Checked
Aug 5, 2026, 11:26 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading